M
Manabu Soda
Researcher at Jichi Medical University
Publications - 32
Citations - 10383
Manabu Soda is an academic researcher from Jichi Medical University. The author has contributed to research in topics: Anaplastic lymphoma kinase & Lung cancer. The author has an hindex of 24, co-authored 32 publications receiving 9616 citations.
Papers
More filters
Journal ArticleDOI
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda,Young Lim Choi,Munehiro Enomoto,Shuji Takada,Yoshihiro Yamashita,Shunpei Ishikawa,Shin-ichiro Fujiwara,Hideki Watanabe,Kentaro Kurashina,Hisashi Hatanaka,Masashi Bando,Shoji Ohno,Yuichi Ishikawa,Hiroyuki Aburatani,Toshiro Niki,Yasunori Sohara,Yukihiko Sugiyama,Hiroyuki Mano +17 more
TL;DR: It is shown that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.
Journal ArticleDOI
RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi,Manabu Soda,Yuki Togashi,Ritsuro Suzuki,Seiji Sakata,Satoko Hatano,Reimi Asaka,Wakako Hamanaka,Hironori Ninomiya,Hirofumi Uehara,Young Lim Choi,Yukitoshi Satoh,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Hiroyuki Mano,Hiroyuki Mano,Yuichi Ishikawa +17 more
TL;DR: A multivariate analysis of 1,116 adenocarcinomas containing 71 kinase-fusion–positive adenokcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathological stage and negative kinase -fusion status.
Journal ArticleDOI
Oncogenic mutations of ALK kinase in neuroblastoma.
Yuyan Chen,Junko Takita,Young Lim Choi,Motohiro Kato,Miki Ohira,Masashi Sanada,Lili Wang,Manabu Soda,Akira Kikuchi,Takashi Igarashi,Akira Nakagawara,Yasuhide Hayashi,Hiroyuki Mano,Seishi Ogawa +13 more
TL;DR: It is demonstrated that downregulation of ALK through RNA interference suppresses proliferation of neuroblastoma cells harbouring mutated ALK, and that ALK-specific kinase inhibitors might improve its clinical outcome.
Journal ArticleDOI
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
King Pan Ng,Axel M. Hillmer,Charles Chuah,Charles Chuah,Wen Chun Juan,Tun Kiat Ko,Audrey S.M. Teo,Pramila N. Ariyaratne,Naoto Takahashi,Kenichi Sawada,Yao Fei,Yao Fei,Sheila Soh,Wah Heng Lee,John W.J. Huang,John Carson Allen,Xing Yi Woo,Niranjan Nagarajan,Vikrant Kumar,Anbupalam Thalamuthu,Wan Ting Poh,Ai Leen Ang,Hae Tha Mya,Gee Fung How,L.Y. Yang,Liang Piu Koh,Balram Chowbay,Chia-Tien Chang,V. S. Nadarajan,Wee Joo Chng,Hein Than,Lay Cheng Lim,Yeow Tee Goh,Shenli Zhang,Dianne Poh,Patrick Tan,Patrick Tan,Ju Ee Seet,Mei-Kim Ang,Noan-Minh Chau,Quan Sing Ng,Daniel Shao-Weng Tan,Manabu Soda,Kazutoshi Isobe,Markus M. Nöthen,Tien Yin Wong,Atif Shahab,Xiaoan Ruan,Valere Cacheux-Rataboul,Wing-Kin Sung,Eng Huat Tan,Yasushi Yatabe,Hiroyuki Mano,Hiroyuki Mano,Ross A. Soo,Tan Min Chin,Wan-Teck Lim,Yijun Ruan,Yijun Ruan,S. Tiong Ong +59 more
TL;DR: The results offer an explanation for the heterogeneity of TKI responses across individuals and suggest the possibility of personalizing therapy with BH3 mimetics to overcome BIM-polymorphism–associated TKI resistance.
Journal ArticleDOI
A mouse model for EML4-ALK-positive lung cancer
Manabu Soda,Shuji Takada,Kengo Takeuchi,Young Lim Choi,Munehiro Enomoto,Toshihide Ueno,Hidenori Haruta,Toru Hamada,Yoshihiro Yamashita,Yuichi Ishikawa,Yukihiko Sugiyama,Hiroyuki Mano +11 more
TL;DR: The established transgenic mouse lines that express EML4-ALK specifically in lung alveolar epithelial cells reinforce the pivotal role of EML 4-ALK in the pathogenesis of NSCLC in humans and provide experimental support for the treatment of this intractable cancer with ALK inhibitors.